EBR Systems (ASX:EBR) Secures NTAP Reimbursement Approval
EBR Systems (ASX:EBR) proposes CMS approval of NTAP reimbursement for its WiSE CRT System, advancing US market strategy.
Category: Healthcare
Clarity Pharmaceuticals (ASX:CU6) Treats First Patient in Phase II SECuRE Trial
Clarity Pharmaceuticals (ASX:CU6) begins Phase II SECuRE trial with first patient treated and enhances 67Cu-SAR-bisPSMA formulation.
4DMedical Limited (ASX:4DX) Converts Integral Diagnostics Pilot to Commercial Contract
4DMedical Limited (ASX:4DX) converts pilot program with Integral Diagnostics into a commercial contract, expanding lung imaging technology across Australia.
Visionflex Group Limited (ASX:VFX) Partners with Amplar Health for Virtual Nursing Project
Visionflex Group Limited (ASX:VFX) partners with Amplar Health to supply virtual care technology for aged care homes across Australia.
4DMedical Limited (ASX:4DX) Secures New Industry Contracts and Gains Congressional Recognition
4DMedical Limited (ASX:4DX) wins new industry contracts and is highlighted in US Congressional testimony on VA Healthcare modernization.
Osteopore Limited (ASX:OSX) Secures EU MDR Approval for Custom Implants
Osteopore (ASX:OSX) secures EU MDR approval for custom orthopaedic and cranial implants, expanding its market in Europe.
Nyrada Inc. (ASX:NYR) Progresses Phase I Clinical Trial
Nyrada Inc. (ASX:NYR) advances its Phase I clinical trial to the second cohort, anticipating final readouts in Q3 CY2025.
Atomo Diagnostics Limited (ASX:AT1) Announces National Scale-Up and NZ Launch
Atomo Diagnostics (ASX:AT1) scales national HIV self-test program in Australia and expands into New Zealand through Chemist Warehouse.
Mesoblast (ASX:MSB) Announces U.S. Tariff Exemption for Allogeneic Cell Therapies
Mesoblast (ASX:MSB) announces its allogeneic cell therapies are exempt from U.S. tariffs as ‘U.S. Country of Origin’ products.
Orthocell Limited (ASX:OCC) Receives FDA Clearance for Remplir™
Orthocell (ASX:OCC) secures FDA clearance for Remplir™, enabling entry into the US $1.6 billion nerve repair market.